These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 32457410

  • 21. Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma.
    Morita M, Murase T, Okumura Y, Ueda K, Sakamoto Y, Masaki A, Kawakita D, Tada Y, Nibu KI, Shibuya Y, Inagaki H.
    Histopathology; 2020 Jun; 76(7):1013-1022. PubMed ID: 32129900
    [Abstract] [Full Text] [Related]

  • 22. Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor.
    Bishop JA, Gagan J, Krane JF, Jo VY.
    Head Neck Pathol; 2020 Dec; 14(4):869-875. PubMed ID: 31989433
    [Abstract] [Full Text] [Related]

  • 23. The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.
    Dogan S, Ng CKY, Xu B, Kumar R, Wang L, Edelweiss M, Scott SN, Zehir A, Drilon A, Morris LGT, Lee NY, Antonescu CR, Ho AL, Katabi N, Berger MF, Reis-Filho JS.
    Hum Pathol; 2019 Jun; 88():66-77. PubMed ID: 30946933
    [Abstract] [Full Text] [Related]

  • 24. Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma.
    van Boxtel W, Uijen MJM, Verhaegh GW, Willems SM, Jonker MA, PALGA Group, Schalken JA, van Engen-van Grunsven ICH, van Herpen CML.
    Oral Oncol; 2020 Nov; 110():105018. PubMed ID: 33039794
    [Abstract] [Full Text] [Related]

  • 25. The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
    Skálová A, Stenman G, Simpson RHW, Hellquist H, Slouka D, Svoboda T, Bishop JA, Hunt JL, Nibu KI, Rinaldo A, Vander Poorten V, Devaney KO, Steiner P, Ferlito A.
    Am J Surg Pathol; 2018 Feb; 42(2):e11-e27. PubMed ID: 29076877
    [Abstract] [Full Text] [Related]

  • 26. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
    Di Palma S, Simpson RH, Marchiò C, Skálová A, Ungari M, Sandison A, Whitaker S, Parry S, Reis-Filho JS.
    Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
    [Abstract] [Full Text] [Related]

  • 27. The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases.
    Urano M, Hirai H, Tada Y, Kawakita D, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Sato Y, Saigusa N, Nakaguro M, Hanazawa T, Nagao T.
    Histopathology; 2018 Dec; 73(6):943-952. PubMed ID: 29993139
    [Abstract] [Full Text] [Related]

  • 28. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
    Xu B, Dogan S, Haroon Al Rasheed MR, Ghossein R, Katabi N.
    Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
    [Abstract] [Full Text] [Related]

  • 29. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
    Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham DS, Washburn D, Wong SJ, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Serracino HS, Ross JS, Bowles DW.
    Clin Cancer Res; 2016 Dec 15; 22(24):6061-6068. PubMed ID: 27334835
    [Abstract] [Full Text] [Related]

  • 30. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
    Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D.
    Clin Cancer Res; 2013 Jan 15; 19(2):480-90. PubMed ID: 23186780
    [Abstract] [Full Text] [Related]

  • 31. The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities.
    Alame M, Cornillot E, Cacheux V, Tosato G, Four M, De Oliveira L, Gofflot S, Delvenne P, Turtoi E, Cabello-Aguilar S, Nishiyama M, Turtoi A, Costes-Martineau V, Colinge J.
    Theranostics; 2020 Jan 15; 10(10):4383-4394. PubMed ID: 32292502
    [Abstract] [Full Text] [Related]

  • 32. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology.
    McLean-Holden AC, Rooper LM, Lubin DJ, Magliocca KR, Manucha V, Sadow PM, Tobias J, Vargo RJ, Thompson LDR, Heidarian A, Weinreb I, Wenig B, Gagan J, Hernandez-Prera JC, Bishop JA.
    Head Neck Pathol; 2022 Sep 15; 16(3):657-669. PubMed ID: 34985683
    [Abstract] [Full Text] [Related]

  • 33. Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum.
    Urano M, Nakaguro M, Yamamoto Y, Hirai H, Tanigawa M, Saigusa N, Shimizu A, Tsukahara K, Tada Y, Sakurai K, Isomura M, Okumura Y, Yamaguchi H, Matsubayashi J, Nagao T.
    Am J Surg Pathol; 2019 Jul 15; 43(7):984-994. PubMed ID: 30994537
    [Abstract] [Full Text] [Related]

  • 34. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
    Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U, Kim S.
    JAMA Otolaryngol Head Neck Surg; 2016 May 01; 142(5):489-95. PubMed ID: 26939990
    [Abstract] [Full Text] [Related]

  • 35. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
    Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, Baatenburg de Jong RJ, van den Brekel MWM, van der Velden LA, Witjes MJH, Hoeben A, Willems SM, Bloemena E, Smit LA, Oosting SF, PALGA Group, Jonker MA, Flucke UE, van Herpen CML.
    Int J Cancer; 2018 Aug 15; 143(4):758-766. PubMed ID: 29492965
    [Abstract] [Full Text] [Related]

  • 36. Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
    Rieke DT, Schröder S, Schafhausen P, Blanc E, Zuljan E, von der Emde B, Beule D, Keller U, Keilholz U, Klinghammer K.
    Front Oncol; 2023 Aug 15; 13():1107134. PubMed ID: 37427101
    [Abstract] [Full Text] [Related]

  • 37. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ.
    Cancer; 2016 Sep 01; 122(17):2654-62. PubMed ID: 27284958
    [Abstract] [Full Text] [Related]

  • 38. Oncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33-RET fusions and BRAF V600E mutations.
    Bishop JA, Nakaguro M, Whaley RD, Ogura K, Imai H, Laklouk I, Faquin WC, Sadow PM, Gagan J, Nagao T.
    Histopathology; 2021 Sep 01; 79(3):338-346. PubMed ID: 33135196
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Sclerosing Polycystic "Adenosis" of Salivary Glands: A Neoplasm Characterized by PI3K Pathway Alterations More Correctly Named Sclerosing Polycystic Adenoma.
    Bishop JA, Gagan J, Baumhoer D, McLean-Holden AL, Oliai BR, Couce M, Thompson LDR.
    Head Neck Pathol; 2020 Sep 01; 14(3):630-636. PubMed ID: 31605313
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.